Celldex Therapeutics Inc (FRA:TCE2) Stock News, Headlines & Updates
Celldex Therapeutics Inc Stock News from GuruFocus
- 1
Jun 16, 2025
CLDX: HC Wainwright Reiterates Buy Rating with $50 Price Target | CLDX Stock News
GuruFocus News • 11:01am
Celldex (CLDX) Shows Promising 52-Week Data in Urticaria Treatment | CLDX Stock News
GuruFocus News • 7:45pm
Jun 14, 2025
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Treating Chronic Spontaneous Urticaria | CLDX stock news
GuruFocus News • 11:00am
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewswire • 11:00am
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Treating Chronic Spontaneous Urticaria | CLDX stock news
GuruFocus News • 10:00am
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 | CLDX Stock News
GuruFocus News • 10:00am
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Marketwired • 10:00am
Jun 13, 2025
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News
GuruFocus News • 7:30am
Jun 12, 2025
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Chronic Spontaneous Urticaria | CLDX stock news
GuruFocus News • 6:04pm
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Marketwired • 6:00pm
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 | CLDX Stock News
GuruFocus News • 5:15pm
Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News
GuruFocus News • 5:15pm
Jun 10, 2025
Celldex Therapeutics Inc (CLDX) Announces Presentation of Phase 2 Study Data at EAACI Congress 2025 | CLDX stock news
GuruFocus News • 4:07pm
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Marketwired • 4:00pm
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress | CLDX Stock News
GuruFocus News • 3:18pm
Jun 06, 2025
Celldex Therapeutics Inc (CLDX) Welcomes Denice M. Torres to Board of Directors | CLDX stock news
GuruFocus News • 8:03am
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Marketwired • 8:00am
Celldex (CLDX) Welcomes Denice Torres to Board of Directors | CLDX Stock News
GuruFocus News • 7:30am
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors | CLDX Stock News
GuruFocus News • 7:16am
May 11, 2025
Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Estimate, Revenue Falls Short at $0.7 Million
GuruFocus News • 7:01pm
May 09, 2025
UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | CLDX Stock News
GuruFocus News • 6:01pm
Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News
GuruFocus News • 1:33pm
Morgan Stanley Updates Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News
GuruFocus News • 11:04am
Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Maintains Buy Rating | CLDX Stock News
GuruFocus News • 7:01am
Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Report | CLDX Stock News
GuruFocus News • 5:46am
Decoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT Insight
GuruFocus News • 11:37pm
May 08, 2025
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
Marketwired • 4:00pm
Celldex (CLDX) Reports Lower-than-Expected Q1 Revenue | CLDX Stock News
GuruFocus News • 3:55pm
May 06, 2025
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News
GuruFocus News • 6:31am
May 05, 2025
Celldex (CLDX) Highlights Promising Phase 2 Study Data for Eosinophilic Esophagitis | CLDX Stock News
GuruFocus News • 4:45pm
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
Marketwired • 4:00pm
Apr 28, 2025
Canaccord Initiates Coverage on Celldex (CLDX) with a Positive Outlook | CLDX Stock News
GuruFocus News • 5:15am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news